Child Who Underwent CAR-T Cancer Therapy Remains Disease-Free After 18 Years

Watch Child Who Underwent CAR-T Cancer Therapy Remains Disease-Free After 18 Years - Rizzle on Dailymotion

Transcript

00:00Child who underwent CAR-T cancer therapy remains disease-free after 18 years.

00:05An 18-year neuroblastoma survivor, marking possibly the longest CAR-T remission,

00:10highlights the therapy's potential.

00:14A 4-year-old girl's treatment with modified T-cells for rare nerve cell cancer

00:19resulted in long-term remission, highlighting potential record survival in CAR-T cancer therapy

00:24nearly two decades later.

00:27Carl June highlights CAR-T's potential for neuroblastoma.

00:30In Heslop's trial, 2004-2009, 19 children were treated, 12 relapsed, and died within 7 years.

00:39One patient survived over 18 years, illustrating CAR-T's promise despite challenges.

00:47In CAR-T cancer therapy, patient T-cells are engineered with CARs and reintroduced.

00:52These CAR-T cells recognize and destroy cancer cells by binding to specific cancer surface

00:57proteins, offering a targeted treatment approach.

01:01CAR-T cancer therapy targets CD19 or BMCA on B cells, reducing toxicity to other tissues.

01:08It's effective in blood cancers, but limited against solid tumors due to antigen selection,

01:13tolerability, and safety issues, necessitating design improvements for enhanced efficacy.

01:18Neuroblastoma is a rare solid tumor affecting children, often relapsing.

01:27Researchers modified T-cells to target GD2, a protein overproduced in these tumors.

01:32This method used activated T-cells and EBV-specific T-cells with detectable CAR transgenes in blood long-term.

01:39The study evidences long-term survival in neuroblastoma children treated with GD2 CAR-T therapy,

01:48with an 18-year remission as the longest for a solid tumor.

01:52Ongoing research promises more results and insights.